Floatz logo

Theprubicin

Angioimmunoblastic T-Cell Lymphoma

Ruijin HospitalSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the Angioimmunoblastic T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Isocyclophosphamide
Shandong Provincial Hospital
Phase 4BBB
Dexasone
Ou Bai, MD/PHD
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 4BB
Adriamycin
City of Hope Medical Center
Phase 4BB
Prednisone
Shanghai Jiao Tong University School of Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Theprubicin is also rated in:

hepatocellular carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →
ALK-negative anaplastic large cell lymphomaDormant
BB
Indicative · Phase 4
65 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →